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Abstract 
Multi-drug resistant (MDR) Klebsiella pneumoniae represent a global threat to healthcare due to 
lack of effective treatments and high mortality rates. The aim of this research was to explore the 
potential of administering zidovudine (AZT) in combination with an existing antibiotic to treat 
resistant K. pneumoniae infections. Two MDR K. pneumoniae strains were employed, producing 
either the NDM-1 or KPC-3 carbapenemase. Efficacy of combinations of AZT with meropenem were 
compared with monotherapies against infections in Galleria mellonella larvae by measuring larval 
mortality and bacterial burden. The effect of the same combinations in vitro was determined via 
checkerboard and time-kill assays. In vitro, both K. pneumoniae strains were resistant to 
meropenem but were susceptible to AZT. In G. mellonella, treatment with either AZT or meropenem 
alone offered minimal therapeutic benefit against infections with either strain. In contrast, 
This is a pre-copyedited, author-produced version of an article accepted for publication in Pathogens and Disease following peer review. 
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combination therapy of AZT with meropenem presented significantly enhanced efficacy compared 
to monotherapies. This was correlated with prevention of bacterial proliferation within the larvae but 
not elimination. Checkerboard assays showed that the interaction between AZT and meropenem 
was not synergistic but indifferent. In summary, combination therapy of AZT with meropenem 
represents a potential treatment for carbapenemase-producing MDR K. pneumoniae and merits 
further investigation.   
Introduction 
Klebsiella pneumoniae belongs to the family Enterobacteriaceae and is part of the normal intestinal 
flora of healthy humans. However, K. pneumoniae is also an important opportunistic pathogen and 
is a major cause of community and healthcare associated infections (HAIs) such as bloodstream, 
urinary tract infections and pneumonias (Navon-Venezia 2017). Infection is often associated with 
invasive medical devices or surgery in patients that are immunocompromised [reviewed in (Peleg 
and Hooper 2010)]. Compounding the problem, K. pneumoniae is adept at acquiring genes 
encoding a range of antibiotic resistance mechanisms via either mutations or mobile genetic 
elements [Navon-Venezia 2017]. Acquisition of resistance to third generation cephalosporins via 
extended-spectrum beta-lactamases (ESBLs) led to increased use of the antibiotics of ‘last-resort’ – 
the carbapenem class of broad-spectrum beta-lactams – resulting in the inevitable selection of 
resistance to these also. With increasing incidence of resistance to carbapenems, the prevalence of 
multi-drug, or extremely- drug resistant (MDR and XDR respectively), K. pneumoniae strains that 
are resistant to nearly all available antibiotics is rising globally (Sanchez 2013). Consequently, there 
are only a limited number of antibiotic treatments available (Morrill 2015) resulting in higher mortality 
rates (Munoz-Price 2013; Tamma 2017) and unsurprisingly, MDR or XDR K. pneumoniae are 
considered an urgent public health threat and a major challenge to the delivery of safe healthcare 
(World Health Organisation 2017).  
The dearth of novel antibiotic treatments in the pipeline for Gram-negative bacteria means that the 
development of alternative treatments based on innovative use of existing drugs is an option. 
Clinically, the administration of antibiotic combinations to patients suffering from MDR or XDR K. 
pneumoniae infection is often employed as a solution to improve therapeutic outcomes. However, 
agreement on the best combinations to use, and evidence of any real benefit, is contested (Tamma 
2012). Examples of combination therapies employed with some success include, dual carbapenem 
therapy (Souli 2017), ceftazidime with avibactam (Lagace-Wiens 2014), meropenem with 
vaborbactam (Lee and Baker 2018), and the polymyxin colistin combined with other antibiotics 
(Gutierrez-Gutierrez 2017). Unfortunately, none of these options are ideal particularly because of 
the nephrotoxicity and rise of resistance associated with colistin (Capone 2013), and the inability of 
either avibactam or vaborbactam to inhibit metallo-beta-lactamases such as NDM-1. Thus, there is 
an urgent clinical need to identify new treatment approaches for MDR or XDR K. pneumoniae 
strains that have acquired carbapenemases. 
To improve options available for clinicians, the ‘repurposing’ of already approved drugs, whose 
primary use is not as antibacterials, as antibiotics could speed up the introduction of new treatment 
options, particularly if these compounds are administered in combinations with existing antibiotics 
(Cheng 2019; Ejim 2011). One example of a drug that could be ‘repurposed’ as an antibiotic is the 
anti-viral drug zidovudine (AZT). AZT is a nucleoside analogue with known bactericidal activity 
against Gram-negative bacteria, including K. pneumoniae (Elwell 1987; Lewin and Aymes 1989; 
Peyclit 2018). In addition, the drug was efficacious in a mouse model of systemic Escherichia coli 
infection (Keith 1989). Upon entering Gram-negative bacterial cells, AZT is phosphorylated by 
thymidine kinases, incorporated into DNA, and arrests replication by acting as a DNA chain 
terminator (Doleans-Jordheim 2011). A number of recent studies that screened libraries of approved 
drugs identified synergistic combinations against Gram-negative bacteria that included AZT (Hind 
2019; Ng 2018; Wambaugh 2017). Synergistic combinations of AZT that inhibited MDR, or XDR, K. 
pneumoniae in vitro included combinations with the lipopeptide antibiotics colistin (Hu 2019) or 
polymyxin B (Lin 2019) that also showed enhanced efficacy compared to monotherapy in murine 
infection models. Despite these studies with the lipopeptide antibiotics, most studies of the effect of 
AZT in combination with existing antibiotics have been performed in vitro. 
The aim of this research was to explore further the potential of administering AZT in combinations 
with existing antibiotics to treat infections with MDR pathogens using the Galleria mellonella larvae 
infection model. This system permits screening of antibacterial activity in vivo against real infections, 
in the presence of a functioning immune system, without the high costs and ethical issues 
associated with mammalian infection models. Thus, combination treatments consisting of AZT with 
the carbapenem beta-lactam, meropenem, were screened for enhanced efficacy compared to 
monotherapies in Galleria mellonella larvae infected with carbapenemase-producing strains of K. 
pneumoniae.  
Materials and Methods 
Bacteria and growth media 
K. pneumoniae strains were obtained from the National  Collection of Type Cultures (NCTC;
https://www.phe-culturecollections.org.uk/collections/nctc.aspx): NCTC 9633T, an antibiotic 
susceptible Type strain, NCTC 13443, producing the NDM-1 metallo-beta-lactamase, and NCTC 
13438, producing the KPC-3 carbapenemase (Woodford 2008). NCTC 9633T was included as a 
control to illustrate the resistance of the two carbapenemase strains to meropenem. All strains were 
grown to stationary phase in Mueller–Hinton broth (MHB; Merck, Darmstadt, Germany) at 37oC with 
shaking (at 200 rpm) overnight to prepare inocula for antibiotic efficacy testing in vitro or in vivo. 
Drugs and G. mellonella larvae 
Meropenem and zidovudine were purchased from Sigma–Aldrich Ltd (Dorset, UK). Stock solutions 
of meropenem or AZT were prepared in sterile deionized water with 10% dimethylsulphoxide. Sub-
stocks of each drug for injection into larvae were prepared in deionized water. G. mellonella larvae 
were obtained from UK Waxworms Ltd (Sheffield, UK). 
Antibiotic susceptibility testing in vitro 
Minimum inhibitory concentrations (MICs) of antibiotics against the K. pneumoniae strains were 
determined in 96-well microplates as previously described (Hill 2014). Briefly, doubling dilutions of 
meropenem or zidovudine were prepared in MHB and subsequently inoculated with 1.0 x 106 
cfu/mL of either K. pneumoniae strain. Microplates were incubated at 37oC and the MIC was defined 
as the concentration(s) present in the first optically clear well after 24 h. 
Testing combinations for synergy in vitro 
The effect of combinations of meropenem with AZT against both K. pneumoniae strains was carried 
out using 96-well microplate assays prepared via doubling dilution of meropenem in MHB followed 
by subsequent addition of AZT to form a combination checkerboard. Each well was then inoculated 
with 1.0 x 106 cfu/mL of either K. pneumoniae strain and microplates were incubated at 37ºC. After 
24 h, each well was scored for visible growth and fractional inhibitory concentration index (FICI) 
values were calculated for each combination tested. Synergy was defined as FICI ≤0.5 (Eliopoulos 
1996). Each K. pneumoniae strain was tested in duplicate. 
The effect of meropenem and AZT combinations against both K. pneumoniae strains was also 
measured using a time-kill assay. Briefly, tubes containing concentrations of AZT, meropenem or a 
combination of both drugs were prepared in MHB broth. A control tube contained only sterile water 
in MHB. Drug concentrations were prepared at MIC50 for each strain. Tubes were then inoculated 
with 1.0 x 107 cfu/mL of either K. pneumoniae strain. Viability was determined after 0, 2, 4 and 6 h 
incubation at 37°C by serial dilution in MHB and plating on Nutrient Agar (Merck, Darmstadt, 
Germany). Each experiment was performed in duplicate and results expressed as mean ± standard 
error of the mean (SEM).  
G. mellonella infection model
Efficacy of meropenem or AZT alone or in combination versus G. mellonella larvae infected with the 
K. pneumoniae strains was carried out exactly as described previously (Hill 2014; Krezdorn 2014;
Adamson 2015). G. mellonella at their final instar larval stage were kept at room temperature in 
darkness. Larvae weighing within the range of 250 to 350 mg were selected for each experiment to 
ensure consistency in subsequent drug administration and were used within 1 week of receipt.  
Groups of 15 larvae were infected with inocula (10 µL) of either K. pneumoniae strain containing 
increasing numbers of bacteria to determine an appropriate infectious dose for subsequent drug 
efficacy studies. Control experiments using a heat-killed inoculum of each strain was carried out in 
which the bacterial suspension was heated at 98ºC for 10 min prior to infection of a group of larvae. 
For all studies of drug efficacy, an inoculum of 5.6 x 105 cfu, or 9.1 x 107 cfu, was used for K. 
pneumoniae NCTC 13443 (NDM-1) and NCTC 13438 (KPC-3), respectively. A single treatment with 
phosphate-buffered saline (PBS), meropenem, AZT or a combination of both drugs was 
administered 2 h post-infection. The experiments were repeated in duplicate using larvae from a 
different batch and the data from these replicate experiments were pooled to give n=30. Survival 
data were plotted using the Kaplan–Meier method (Bland and Altman 1998) and comparisons made 
between groups using the log-rank test (Bland 2004). In all comparisons with the negative control it 
was the uninfected control (rather than the unmanipulated control) that was used. Holm’s correction 
was applied to account for multiple comparisons in all tests and p ≤ 0.05 was considered significant 
(Holm 1979).  
Bacterial burden within larvae from each treatment group was measured exactly as described 
previously (Krezdorn 2014; Adamson 2015; Ballard and Coote 2016). Groups of 30 larvae were 
infected with either strain of K. pneumoniae using the same inoculum sizes as described above. 
Meropenem, AZT or a combination treatment of both drugs were administered at 2 h post-infection. 
Larvae were incubated in Petri dishes at 37°C. At 24 h intervals, five larvae were randomly selected 
from each treatment group and surface decontaminated and anaesthetised by washing in absolute 
ethanol. Each larva was then placed in an Eppendorf tube containing 1 mL of sterile PBS and 
homogenised using a sterile pestle. Bacterial burden from individual caterpillars was then 
determined by serial dilution of the homogenate in MHB and plating on MacConkey agar 
(Formedium Ltd, Hunstanton, England). The detection limit for this assay was 100 cfu/mL of larval 
homogenate. 
Results 
Two carbapenemase-producing strains of K. pneumoniae are resistant to meropenem but 
sensitive to the antiviral drug AZT. In comparison to the antibiotic-susceptible Type strain, the two 
strains producing the carbapenemases displayed resistance to meropenem as expected (Table 1). 
The MICs of meropenem were the same for both carbapenemase-producing strains but K. 
pneumoniae NCTC 13438, carrying the KPC-3 carbapenemase, was more resistant to AZT (4 mg/L) 
than NCTC 13443 with NDM-1 (1 – 2 mg/L). These results confirmed previous studies with different 
strains of K. pneumoniae that showed sensitivity to AZT (Elwell 1987; Lewin and Aymes 1989; 
Peyclit 2018).  
G. mellonella larvae display dose-dependent lethality in response to infection by either strain
of MDR K. pneumoniae. The effect of infection with either K. pneumoniae strains on survival of G. 
mellonella is shown in Figure 1. In both strains, the heat-killed inoculum had no significant effect on 
larval survival (p>0.05). With live inocula, larval survival was affected in a dose-dependent manner 
during 96 h incubation (Figure 1). Together, these data indicate that infection with live K. 
pneumoniae is required to cause larval death and support previous studies that have utilised G. 
mellonella to study infection by different K. pneumoniae strains (Insua 2013; Wand 2013; 
McLaughlin 2014; Benthall 2015). 
K. pneumoniae NCTC 13443 (NDM-1) displayed greater virulence than NCTC 13438 (KPC-3),
requiring a smaller inoculum of viable bacteria to induce a similar degree of lethality to infected 
larvae. Infectious doses for each strain were selected for use in subsequent studies on antibiotic 
efficacy (5.6 x 105 cfu for K. pneumoniae NCTC 13443, and 9.1 x 107 cfu for NCTC 13438) that 
resulted in the death of approximately 90% of larvae after 96 h incubation at 37ºC.  
Efficacy of AZT or meropenem monotherapy in G. mellonella larvae infected with either 
carbapenemase-producing strain of K. pneumoniae is poor. The effect of single doses of AZT 
or meropenem, 2 h post-infection (p.i) with either K. pneumoniae strain, on survival of G. mellonella 
larvae is shown in Figure 2. Both drugs increased larval survival in a dose-dependent manner 
regardless of the K. pneumoniae strain. However, neither drug induced high levels of therapeutic 
benefit, with the exception of AZT versus larvae infected with K. pneumoniae NCTC 13443 (NDM-1) 
treated with the highest doses of 6.25 or 12.5 mg/kg. In contrast, treatment of larvae infected with 
the KPC-3-producing strain with the same doses of AZT had no therapeutic benefit after 120 h. As 
would be expected with these strains, treatment with meropenem induced only low levels of 
therapeutic benefit even at the highest doses tested, particularly against infections with K. 
pneumoniae NCTC 13438 (KPC-3). 
In summary, neither AZT or meropenem monotherapy offered high levels of therapeutic benefit 
versus infections with either strain of carbapenemase-producing K. pneumoniae, although both 
drugs were moderately more effective against the NMD-1-producing strain than the KPC-3 strain. 
Combination therapy with AZT plus meropenem shows enhanced efficacy compared to 
monotherapy versus G. mellonella infections with carbapenemase-producing MDR strains of 
K. pneumoniae. The effect of monotherapy, with AZT or meropenem, compared with combination
therapy on survival of G. mellonella larvae, and burden of infecting bacteria, for both 
carbapenemase-producing strains of K. pneumoniae is shown in Figure 3. Pilot experiments were 
carried out testing many different doses of AZT or meropenem in combination to identify the most 
effective doses to employ against larval infections with either strain of K. pneumoniae (data not 
shown). From these initial studies, optimal combination dosing regimens were selected that offered 
the best therapeutic benefit and subsequently studied in detail – NCTC 13443 (AZT - 0.78 mk/kg + 
meropenem - 6.25 mg/kg) and NCTC 13438 (AZT - 6.25 mg/kg + meropenem - 12.5 mg/kg) (Figure 
3). 
As shown previously (Figure 2), a single dose 2 h p.i of either AZT or meropenem had minimal 
therapeutic benefit on larvae infected with either strain of K. pneumoniae (Figure 3). This was 
reflected in large increases over 24 h in the internal burden of either infecting K. pneumoniae strain 
within individual larvae. For larvae infected with NCTC 13443 (NDM-1), the increase in bacterial 
numbers after treatment with either meropenem or AZT was the same as larvae mock treated with 
PBS. With strain NCTC 13438 (KPC-3), larvae treated with either meropenem or PBS alone also 
displayed an identical increase in bacterial burden after 24 h. Notably, the increase in bacterial 
numbers after treatment with AZT was reduced (approximately 0.5 log10 cfu/mL), indicating some 
inhibitory effect of the drug on proliferation of strain NCTC 13438 within the larvae. However, this 
smaller increase in bacterial numbers post AZT therapy was not reflected in any significant 
reduction in larval death compared to treatment with meropenem or PBS (Figure 3). 
In direct contrast to monotherapies, a single dose of a combination of AZT + meropenem resulted in 
significantly (p ≤ 0.05) enhanced survival of larvae infected with either MDR strain of K. pneumoniae 
(Figure 3). For example, 120 h p.i with NCTC 13443 (NDM-1), populations treated with PBS, AZT 
alone or meropenem alone showed survival of 20, 40 and 47% respectively. In contrast, 67% of 
larvae treated with the combination survived. At the same time p.i with NCTC 13438 (KPC-3), 
treatment with PBS, AZT alone or meropenem alone showed survival of 10, 13 and 17% 
respectively compared to 47% for the combination. Correlating with this enhanced survival, the 
burden of bacteria within the infected larvae did not show the large increase after 24 h observed 
previously with the monotherapies, and, bacterial numbers remained significantly lower throughout 
the duration of the experiment (p ≤ 0.05). Whilst the combination treatment halted the proliferation of 
infecting bacteria of either strain, numbers did not fall below the initial infecting inoculum size. Thus, 
the therapeutic benefit conferred by AZT+ meropenem combination treatment appears to be due to 
a bacteriostatic effect in vivo. 
In summary, a combination treatment of AZT + meropenem offers a potential novel therapy for 
treatment of MDR, carbapenemase-producing strains of K. pneumoniae. 
The inhibitory action of the combination of AZT plus meropenem versus K. pneumoniae is 
not significantly synergistic in vitro. To help understand the nature of the inhibitory action of the 
combination of AZT with meropenem that conferred enhanced efficacy in vivo, checkerboard and 
time-kill experiments were conducted in vitro (Figure 4). A checkerboard assay showing the effect of 
different AZT and meropenem combinations on growth of both carbapenemase-producing strains of 
K. pneumoniae is shown in Figure 4a. For NCTC 13443 (NDM-1), there was some evidence of
minor synergy (FICI ≤ 0.5) at only two combinations tested. The majority of the other combinations 
that inhibited growth did so in an indifferent or additive fashion. For strain NCTC 13438 (KPC-3), 
none of the inhibitory combinations tested were synergistic, with all displaying indifference or 
additivity. 
The effect of exposure to the single drugs (at MIC50) and a combination (also at MIC50 for each drug) 
on viability of both strains is shown in Figure 4b. Bacterial viability was measured over a period of 6 
h at 37°C. Control populations of both strains, mock treated with PBS increased in cell number over 
the duration of the experiment. Exposure to AZT alone resulted in a loss of viability of both strains of 
approximately 3 log10 cfu/mL after 6 h. In contrast, exposure to meropenem also resulted in loss of 
viability, but after 6 h exposure, there was evidence from both strains that the surviving population 
of bacteria was recovering and growth resuming. With both strains, the combination treatment 
resulted in a steady decline in viability of approximately 4 log10 cfu/mL after 6 h. Despite the greater 
bactericidal effect of the combination compared to the individual drugs, the loss of viability induced 
by the combination was only approximately 1 log10 cfu/mL more than AZT alone. This supports the 
checkerboard results by showing that the inhibition of K. pneumoniae induced by exposure to the 
combination of AZT with meropenem is not strongly synergistic. Notably, despite being bactericidal, 
the combination did not eliminate all bacteria over the duration of the experiment. This observation 
is supported by the G. mellonella larval burden assays (Figure 3) where infecting K. pneumoniae 
were never eliminated and a reduced number of bacteria were always detectable.   
Discussion 
The antibacterial properties of AZT have been well documented but the drug has never been 
formally approved to treat bacterial infections (Elwell 1987; Lewin and Aymes 1989; Ng 2018). With 
the emergence of untreatable infections by MDR, or XDR, Gram-negative bacteria, there has been 
renewed interest in exploiting these properties and ‘repurposing’ the drug. In fact, a recent study 
proposed using AZT alone as a salvage therapy for colistin-resistant infections (Peyclit 2018). In this 
study, AZT was shown to inhibit two MDR, carbapenemase-producing strains of K. pneumoniae with 
MICs between 1.0 and 4.0 mg/L, confirming the known inhibitory effect of AZT on this pathogen 
(Elwell 1987; Lewin and Aymes 1989; Peyclit 2018). In addition, G. mellonella larvae infected with 
the same strains displayed enhanced survival after monotherapy with AZT.  
Despite many studies showing that AZT is antibacterial, one reason why the drug may not be highly 
effective as a monotherapy is the induction of resistance after short-term exposure (Lewin 1990). 
AZT only inhibits bacteria that possess a thymidine kinase that phosphorylates the AZT such that it 
can then be incorporated into DNA and arrest DNA replication (Doleans-Jordheim 2011). In E. coli, 
mutations, or the presence of insertion sequences, in the gene encoding thymidine kinase (that 
could result in impaired function of the enzyme) correlated with AZT resistance (Doleans-Jordheim 
2011). Furthermore, E. coli strains resistant to AZT have been isolated from patients undergoing 
therapy with the drug and the activity of thymidine kinase in these strains was reduced (Lewin 1990). 
Thus, because of the issue of resistance to AZT, the most likely application of the drug as an 
antibacterial therapy for MDR Enterobacteriaceae is in combination therapies with antibiotics that 
could help reduce the onset of resistance. 
A number of studies have highlighted effective combinations of AZT with various approved 
antibiotics in vitro including: tigecycline against MDR E. coli and K. pneumoniae (Ng 2018); colistin 
versus colistin-resistant K. pneumoniae (Falagas 2019) or E. coli (Loose 2018; Peyclit 2018); 
trimethoprim and/or sulfamethizole against trimethoprim-resistant E. coli and K. pneumoniae clinical 
isolates (Wambaugh 2017); and the aminoglycosides, gentamicin and amikacin against E. coli 
(Doleans-Jordheim 2011). Notably, two studies demonstrate enhanced efficacy in vivo of AZT in 
combination with colistin (Hu 2019) or polymyxin B (Lin 2019), compared to their constituent 
monotherapies, in murine infection models with NDM-producing K. pneumoniae and/or colistin-
resistant E. coli. In this study, a combination therapy consisting of AZT with meropenem resulted in 
enhanced efficacy against infections by two MDR, carbapenemase-producing strains of K. 
pneumoniae in G. mellonella larvae compared to each monotherapy. Supporting these findings, a 
recent screen of Food and Drug Administration-approved drugs identified that AZT acted as an 
antibiotic-resistance breaker (ARB) when combined with meropenem and potentiated the inhibitory 
effect of the antibiotic against MDR K. pneumoniae in vitro (Hind 2019). Clearly, only two NCTC 
carbapenemase-producing strains were used in this study and additional studies using a range of 
carbapenemase-producing clinical isolates will be required to confirm the enhanced efficacy of this 
combination. 
Despite the enhanced efficacy of the combination, the larval populations treated with the 
combinations still suffered mortality for the duration of the experiments albeit less than those treated 
with the monotherapies. This observation could be explained by the effect the different treatments 
had on the burden of infecting bacteria within the larvae. For example, monotherapies had no 
detrimental effect on the infecting bacteria of either strain because numbers increased rapidly over 
the first 24 h in the same fashion as larvae sham-treated with PBS. However, combination therapy 
had the effect of preventing infecting bacteria of either strain from proliferating in the larvae but, 
notably, did not reduce bacterial burden. The fact that combination-treated larvae still contained 
viable bacteria could account for these populations suffering mortality at a reduced rate compared 
to populations treated with either monotherapy. These observations in vivo were supported by the 
results from the in vitro time-kill experiments. For example, despite the combination of AZT with 
meropenem showing a bactericidal effect, lethality slowed over a 6 h period of exposure and low 
numbers of either strain survived. Furthermore, the enhanced efficacy of the combination treatment 
in vivo was unlikely to be due to a synergistic interaction between AZT and meropenem because 
the in vitro experiments largely showed an indifferent or additive effect. The lack of potent synergy 
between AZT and meropenem versus the two K. pneumoniae strains could account for the 
observed survival kinetics of infected larvae and the failure of the combination treatment to confer 
full survival or eliminate all infecting bacteria at the doses tested. It is likely that the enhanced 
efficacy of the combination observed in vivo can be explained by the FICI values observed in vitro. 
For example, the best FICI value obtained for the NDM-1 strain was 0.5 and for the KPC-3 strain 
0.62. These values represent a weak synergistic effect or, at the very least, an indifferent or additive 
effect of the combination versus both strains. An additive effect is supported by the time-kill assay 
whereby a 6 h exposure to the combination resulted in only approximately 1 log10 cfu/mL greater 
reduction in cell numbers than either of the constituent drugs alone.  
For therapy of Human Immunodeficiency Virus (HIV), AZT is administered orally at 300 mg twice a 
day indicating that blood plasma concentrations above the MIC for K. pneumoniae could be reached 
(Peyclit 2018; Falagas 2019). Furthermore, AZT is well-tolerated, and toxicity generally only 
manifests after long-term use of the drug – a scenario that would be unlikely if antibiotic/AZT 
combinations were used to treat acute bacterial infections.  
In summary, this work has identified that combination of AZT with meropenem represents a 
plausible alternative therapy to treat infections with MDR, carbapenemase-producing strains of K. 
pneumoniae and merits further investigation. 
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Figure 1. Effect of increasing inoculum dose of live K. pneumoniae NCTC 13443 (NDM-1) or NCTC 
13438 (KPC-3) on the survival of G. mellonella larvae during incubation at 37°C for 120 h. Numbers 
in the legend indicate the inoculum size in bacterial cells per larva. For both strains, the effect of 
heat-killed (h.k.) bacterial inocula is also shown. No significant mortality was observed in an 
unmanipulated group (data not shown) or in the uninfected group mock ‘infected’ with sterile PBS. 
For all infected groups, survival was significantly reduced compared to the mock ‘infected’ group 
(p<0.05, log rank test with Holm correction for multiple comparisons); n=30 (pooled from replicate 
experiments). 
Figure 2. Effect of treatment with zidovudine (AZT) or meropenem (MEM) on survival of G. 
mellonella larvae infected with K. pneumoniae strains. Groups of larvae were mock ‘infected’ with 
sterile PBS, or 5.6 x 105 cells of the NDM-1 strain, or 9.1 x 107 cells of the KPC-3 strain. 2 h post-
infection (p.i), a single dose of either MEM or AZT was administered (dose in mg/kg is the number 
shown on the figure). The mock ‘treated’ group represents infected larvae treated with sterile PBS. 
Larval survival was measured over a period of 120 h at 37°C. * indicates significantly enhanced 
survival compared to the mock ‘treated’ group (p<0.05, log rank test with Holm correction for 
multiple comparisons); n=30 (pooled from duplicate experiments). 
Figure 3. Effect of treatment with combinations of AZT and MEM on the survival and internal 
bacterial burden of G. mellonella larvae infected with K. pneumoniae strains. Larvae were infected 
with PBS (mock ‘infected’), K. pneumoniae NCTC 13443 (NDM-1) – 5.6 x 105 cells, or  NCTC 13438 
(KPC-3) – 9.1 x 107 cells and treated with either PBS (mock ‘treated’), or a single dose of each drug 
individually, or a combination of MEM and AZT at 2 h p.i. (dose in mg/kg is the number shown on 
the figure). Larvae were incubated at 37oC for 120 h and survival recorded every 24 h.  
The larval burden of K. pneumoniae was determined from five individual larvae per treatment group 
every 24 h for 96 h at 37oC. Error bars indicate ±SEM.  
* combination treatment group with significantly enhanced survival compared with any of the
constituent monotherapies (p < 0.05, log-rank test with Holm’s correction for multiple comparisons). 
n=30 (pooled from duplicate experiments).  
# significant difference in larval burden between groups treated with the combination of AZT + MEM 
compared with each monotherapy (p < 0.05, the Mann–Whitney U-test compared the combination 
therapy with each monotherapy). n = 5. 

Figure 4. The effect of combination of AZT with MEM on the growth and viability of K. pneumoniae 
NCTC 13443 (NDM-1) or NCTC 13438 (KPC-3) in vitro. Fractional inhibitory concentration indices 
(FICI) of AZT combined with MEM versus NDM-1 and KPC-3 after 24 h in MHB at 37oC (A). Black 
squares indicate FICI values where bacterial growth occurred. Grey squares indicate wells where 
the FICI values were ≥ 0.5 (indicating inhibition was not synergistic). White squares show FICI 
values of 0.5 or less where bacterial growth was inhibited and thus indicate synergistic inhibition of 
growth. The experiment was performed in duplicate and a representative result is shown.  
Time-kill curves of the effect of 6 h exposure to PBS or MIC50 of; MEM alone (128 mg/L for both 
NDM-1 and KPC-3); AZT alone (0.5 mg/L NDM-1 and 2 mg/L KPC-3) or AZT + MEM (NDM-1 – 128 
mg/L MEM + 0.5 mg/L AZT; KPC-3 – 128mg/L MEM + 2 mg/L AZT). Error bars indicate ±SEM from 
duplicate experiments (B). 
Table 1 – Minimum inhibitory concentration (MIC) of zidovudine (AZT) and meropenem (MEM) for 
the K. pneumoniae Type strain or strains possessing either the NDM-1 or KPC-3 carbapenemases. 
Bacterial Strains  MIC (mg/L) 
AZT MEM 
K. pneumoniae NCTC 9633T - <0.0625 
K. pneumoniae NCTC 13443 (NDM-1) 1.0 – 2.0 128 - 256 
K. pneumoniae NCTC 13438 (KPC-3) 4.0 128 - 256 
